Address: 1-1 Nihonbashi-Muromachi 2-Chome
Chuo-ku, Tokyo 103-8324
Chugai Pharmaceutical’s mission is to add exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.
Oncology, renal diseases, and bone and joint diseases are positioned as Chugai’s strategic areas. The company is undertaking measures to create original and innovative drugs, both in Japan and overseas, particularly to address unmet medical needs, where the level of pharmaceutical contribution and satisfaction concerning patient treatment remains low. This is accomplished by effectively leveraging the resources of the Roche Group, while they pursue cutting-edge biopharmaceutical, antibody, and molecular targeted research technologies—areas that constitute Chugai’s greatest strengths—as well as chemical synthesis technology.
They aim to become a top Japanese pharmaceutical company with global-level capabilities.
In 2012 Chugai will spend some S$200 million on antibody research in Singapore over the next five years. To set up Chugai Pharmabody Research to develop antibody drugs for cancer treatment and other diseases. This is the firm’s second satellite research institute in Singapore.
Products and services
Pharma and biopharma